Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Nov;36(11):2381–2386. doi: 10.1128/aac.36.11.2381

Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection.

K K Van Rompay 1, M L Marthas 1, R A Ramos 1, C P Mandell 1, E K McGowan 1, S M Joye 1, N C Pedersen 1
PMCID: PMC284339  PMID: 1489181

Abstract

The prophylactic and therapeutic properties of 3'-azido-3'-deoxythymidine (AZT) against simian immunodeficiency virus (SIV) infection were tested in four 3-month-old rhesus macaques. The infant monkeys were inoculated intravenously with a low dose (1 to 10 100% animal infectious doses) of uncloned SIVmac. The monkeys were treated orally with 50 mg of AZT per kg of body weight every 8 h; two animals were started on treatment 2 h prior to virus inoculation, and two animals were started on treatment 6 weeks later. All four animals were treated for a period of 6 to 10 weeks. Outward signs of AZT toxicity were absent, but a mild macrocytic anemia occurred soon after therapy was started and resolved shortly after it was discontinued. The two infants that were begun on AZT treatment 2 h prior to virus inoculation never became infected, as demonstrated by the inability to detect cell-free or cell-associated virus in the blood, proviral DNA in peripheral blood mononuclear cells, or anti-SIV antibodies. AZT administration over a 10-week period had no detectable effect on the course of disease in the two animals that were begun on treatment after the infection had been established. In addition to demonstrating the prophylactic effect of AZT against low-dose SIV exposure, the study demonstrated the ease with which infant rhesus macaques can be used for antiretroviral drug testing.

Full text

PDF
2381

Images in this article

2383Image
on p.2383

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alimenti A., Luzuriaga K., Stechenberg B., Sullivan J. L. Quantitation of human immunodeficiency virus in vertically infected infants and children. J Pediatr. 1991 Aug;119(2):225–229. doi: 10.1016/s0022-3476(05)80731-0. [DOI] [PubMed] [Google Scholar]
  2. Blum M. R., Liao S. H., Good S. S., de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988 Aug 29;85(2A):189–194. [PubMed] [Google Scholar]
  3. Daar E. S., Moudgil T., Meyer R. D., Ho D. D. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991 Apr 4;324(14):961–964. doi: 10.1056/NEJM199104043241405. [DOI] [PubMed] [Google Scholar]
  4. Fazely F., Haseltine W. A., Rodger R. F., Ruprecht R. M. Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon-alpha: failure after inoculating rhesus monkeys with a high dose of SIV. J Acquir Immune Defic Syndr. 1991;4(11):1093–1097. [PubMed] [Google Scholar]
  5. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  6. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gardner M. B. Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents. Antiviral Res. 1991 May;15(4):267–286. doi: 10.1016/0166-3542(91)90009-g. [DOI] [PubMed] [Google Scholar]
  8. Gerberding J. L., Henderson D. K. Management of occupational exposures to bloodborne pathogens: hepatitis B virus, hepatitis C virus, and human immunodeficiency virus. Clin Infect Dis. 1992 Jun;14(6):1179–1185. doi: 10.1093/clinids/14.6.1179. [DOI] [PubMed] [Google Scholar]
  9. Ho D. D., Moudgil T., Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989 Dec 14;321(24):1621–1625. doi: 10.1056/NEJM198912143212401. [DOI] [PubMed] [Google Scholar]
  10. Kupferschmidt R., Schmid R. W. Specific routine determination of 3'-azido-3'-deoxythymidine (AZT) in plasma by partly automated liquid chromatography. Clin Chem. 1989 Jul;35(7):1313–1317. [PubMed] [Google Scholar]
  11. Lohman B. L., Higgins J., Marthas M. L., Marx P. A., Pedersen N. C. Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J Clin Microbiol. 1991 Oct;29(10):2187–2192. doi: 10.1128/jcm.29.10.2187-2192.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lopez-Anaya A., Unadkat J. D., Schumann L. A., Smith A. L. Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate. J Acquir Immune Defic Syndr. 1990;3(11):1052–1058. [PubMed] [Google Scholar]
  13. Lundgren B., Böttiger D., Ljungdahl-Ståhle E., Norrby E., Ståhle L., Wahren B., Oberg B. Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr. 1991;4(5):489–498. [PubMed] [Google Scholar]
  14. Marthas M. L., Miller C. J., Sutjipto S., Higgins J., Torten J., Lohman B. L., Unger R. E., Ramos R. A., Kiyono H., McGhee J. R. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J Med Primatol. 1992 Feb-May;21(2-3):99–107. [PubMed] [Google Scholar]
  15. McClure H. M., Anderson D. C., Ansari A. A., Fultz P. N., Klumpp S. A., Schinazi R. F. Nonhuman primate models for evaluation of AIDS therapy. Ann N Y Acad Sci. 1990;616:287–298. doi: 10.1111/j.1749-6632.1990.tb17849.x. [DOI] [PubMed] [Google Scholar]
  16. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. O'Shea S., Rostron T., Hamblin A. S., Palmer S. J., Banatvala J. E. Quantitation of HIV: correlation with clinical, virological, and immunological status. J Med Virol. 1991 Sep;35(1):65–69. doi: 10.1002/jmv.1890350114. [DOI] [PubMed] [Google Scholar]
  18. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  19. Sutjipto S., Pedersen N. C., Miller C. J., Gardner M. B., Hanson C. V., Gettie A., Jennings M., Higgins J., Marx P. A. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J Virol. 1990 May;64(5):2290–2297. doi: 10.1128/jvi.64.5.2290-2297.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Unadkat J. D., Crosby S. S., Wang J. P., Hertel C. C. Simple and rapid high-performance liquid chromatographic assay for zidovudine (azidothymidine) in plasma and urine. J Chromatogr. 1988 Sep 9;430(2):420–423. doi: 10.1016/s0378-4347(00)83180-1. [DOI] [PubMed] [Google Scholar]
  21. Unger R. E., Marthas M. L., Lackner A. A., Pratt-Lowe E., Lohman B. L., Van Rompay K., Luciw P. A. Detection of simian immunodeficiency virus DNA in macrophages from infected rhesus macaques. J Med Primatol. 1992 Feb-May;21(2-3):74–81. [PubMed] [Google Scholar]
  22. Vella P. P., Ellis R. W. Immunogenicity of Haemophilus influenzae type b conjugate vaccines in infant rhesus monkeys. Pediatr Res. 1991 Jan;29(1):10–13. doi: 10.1203/00006450-199101000-00003. [DOI] [PubMed] [Google Scholar]
  23. Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES